Cone-rod dystrophy 17 is a genetic eye condition that affects how the retina senses light and color. People with cone-rod dystrophy 17 often notice blurred vision, light sensitivity, and trouble seeing colors, with night vision problems developing later. Symptoms usually begin in childhood or adolescence and tend to worsen over time. There is no cure, but tinted lenses, magnification, low-vision aids, and vision rehabilitation can help daily life. Not everyone will have the same experience, and most people live a normal lifespan with regular eye care and support.
Overview
Cone-rod dystrophy 17Symptoms
Cone-rod dystrophy 17 causes progressive vision problems. Early symptoms often include blurred central vision, light sensitivity, and trouble seeing colors. Over time, many develop night blindness and shrinking side vision, making reading, driving, and recognizing faces harder.
Outlook and prognosis
Many living with cone-rod dystrophy 17 notice vision changes that slowly progress, often starting with color and central vision and later affecting night and side vision. The timeline varies widely by gene variant and family pattern. Regular eye care, vision aids, and low‑vision rehab help maintain independence.
Causes and risk factors
Cone-rod dystrophy 17 results from a disease-causing change in a gene, usually inherited; some cases arise as new mutations. The main risk factor is family history, with higher risk in consanguineous families; lifestyle doesn’t cause it.
Genetic influences
Genetics play a central role in cone-rod dystrophy 17; it’s caused by inherited changes in a specific gene. Variants can affect age of onset, severity, and vision loss pattern. Family history matters, so genetic testing and counseling are often recommended.
Diagnosis
Doctors suspect Cone-rod dystrophy 17 from eye findings and vision testing. Retinal imaging and electroretinography document cone-rod dysfunction. Genetic testing confirms the diagnosis, often using panels, supporting the genetic diagnosis of Cone-rod dystrophy 17.
Treatment and drugs
Treatment for cone-rod dystrophy 17 focuses on protecting remaining vision, easing symptoms, and supporting daily tasks. This often includes tinted or polarized lenses for light sensitivity, low-vision aids, orientation training, and regular retina care. Genetic counseling and clinical-trial enrollment may also be considered.
Symptoms
Cone-rod dystrophy 17 can affect daily tasks that rely on sharp central vision, color, and comfortable light levels. It often begins with difficulties seeing fine details and distinguishing colors, and later can involve night and side vision. Features vary from person to person and can change over time.
Many start with reduced sharpness in the center of what they see. Early features of Cone-rod dystrophy 17 often include trouble reading fine print. Faces can become harder to recognize even with updated glasses.
Colors can look faded or mixed up. Reds and greens or blues and yellows may be harder to tell apart. This can make choosing ripe fruit or matching clothes more challenging.
Bright light and glare feel uncomfortable. Indoor lighting may seem too harsh, and sunlight can be dazzling. Sunglasses, brimmed hats, or tinted lenses often help reduce discomfort.
Dim rooms and dusk are harder to navigate. It can take longer for eyes to adjust after lights go off. Driving at night can become stressful or unsafe for many with Cone-rod dystrophy 17.
How people usually first notice Cone-rod dystrophy 17?
Many first notice cone-rod dystrophy 17 when reading or recognizing faces becomes harder, colors look dull or “washed out,” or bright light and glare feel uncomfortably intense, often starting in childhood or the teen years. Eye exams typically reveal reduced central vision and abnormal color vision before night vision and side (peripheral) vision problems appear, and an ophthalmologist may see characteristic changes in the retina on detailed imaging. If there’s a family history, genetic testing is often used to confirm the diagnosis after these first signs of cone-rod dystrophy 17 show up.
Types of Cone-rod dystrophy 17
Cone-rod dystrophy 17 is a genetic eye condition with recognized clinical variants tied to different gene changes. These variants can affect how early vision problems start, which symptoms show up first, and how quickly they progress. People may notice different sets of symptoms depending on their situation. When learning about types of Cone-rod dystrophy 17, it helps to know that some variants are linked to inheritance patterns that run in families, which can shape both severity and age of onset.
Autosomal dominant
This variant is passed down when a single altered gene from one parent is enough to cause the condition. Symptoms often start in later childhood or adulthood, with early color vision loss, light sensitivity, and central blur.
Autosomal recessive
This variant occurs when both copies of the gene are altered, typically leading to earlier onset and faster progression. People may develop reduced central vision and color discrimination in childhood, followed by night vision problems as rods become involved.
X-linked
This variant is tied to a gene on the X chromosome, so males are usually more affected while females can have milder or variable symptoms. Boys often develop early central vision loss and color difficulties, with rod symptoms such as night blindness emerging over time.
Early-onset form
Symptoms begin in infancy or early childhood, with rapid decline in color and central vision. Nystagmus and strong light sensitivity can appear early, and rod-related issues like night blindness tend to follow sooner.
Later-onset form
Symptoms emerge in the teens or adulthood and progress more gradually. People may first notice trouble with fine detail and color, then sensitivity to glare, with night vision changes developing later.
What genetics can tell you about symptoms
In cone-rod dystrophy 17, changes in the CDHR1 gene disrupt light-sensing cells, so many first notice blurred central vision, trouble reading, and poor color perception, followed later by night blindness and side vision loss. Specific variants often predict earlier onset and faster progression.
Causes and risk factors
Cone-rod dystrophy 17 is usually caused by a change in a single gene that disrupts how the retina’s cone and rod cells work. This change can be inherited from a parent, or it can arise as a new gene change. A family history raises risk, and knowing this can help you watch for early symptoms of cone-rod dystrophy 17. Long hours in bright light and smoking may add stress to the retina and can influence how quickly symptoms progress, but they are not the cause. Some risks are modifiable (things you can change), others are non-modifiable (things you can’t).
Environmental and biological risk factors
Cone-rod dystrophy 17 is a rare eye condition. When we look at what increases the chance of it occurring, very few outside factors have been proven to matter. Doctors often group risks into internal (biological) and external (environmental). The points below focus on those influences on occurrence, and they don’t change the early symptoms of Cone-rod dystrophy 17.
Random DNA changes can arise when eggs or sperm form. These rare events can lead to Cone-rod dystrophy 17. The absolute chance is low for any single pregnancy.
As paternal age increases, new DNA changes in sperm become slightly more frequent. This can marginally raise the chance of a condition occurring for the first time in a family. The overall effect is small.
Exposure of the reproductive organs to high-dose ionizing radiation can increase the number of DNA changes in eggs or sperm. Everyday medical imaging uses far lower doses and is not linked to increased risk. Such exposure is uncommon and typically related to cancer therapy or major accidents.
Common environmental exposures in pregnancy are not known to cause Cone-rod dystrophy 17. Some toxins and infections can harm developing eyes in other ways, so avoiding known hazards remains wise. Routine prenatal care helps reduce unrelated eye risks.
Genetic risk factors
When vision changes run in a family, the next question is often, “Is it genetic and who else is at risk?” Cone-rod dystrophy 17 is linked to changes in a single retina gene, so risk tends to follow family lines rather than lifestyle. Some risk factors are inherited through our genes. If early symptoms of Cone-rod dystrophy 17 appear in childhood or the teen years, DNA testing can often identify the exact change and clarify risks for relatives.
Single-gene change: Many cases of Cone-rod dystrophy 17 trace to a disease-causing change in one retinal gene. This change disrupts how cone and rod cells work. Confirming the exact change helps estimate risks for relatives.
Family history clues: Having relatives with early-onset retinal problems raises the chance that a shared gene change is present. Patterns across generations help indicate who in the family may be at increased risk. A genetics professional can review family history to clarify this.
Variant type matters: Some changes stop the gene from making a working protein, while others tweak its function. These differences can shape the age when problems begin and how quickly they progress. They also influence which relatives are most likely to be affected.
Variable expression: People with the same gene change can have different levels of vision loss and ages at onset. This helps explain why early symptoms of Cone-rod dystrophy 17 may show up at different times in the same family. Doctors consider this when discussing prognosis.
Incomplete penetrance: Not everyone who carries a CORD17-related change will develop clear symptoms. This can make family history look skipped across generations. Genetic testing can reveal hidden risk even when vision seems normal.
De novo changes: In some children, the gene change appears for the first time and is not found in either parent. When this happens, sibling risk is usually low. Testing parents helps confirm this scenario.
Sibling and child risk: First-degree relatives have a higher chance of sharing the causal change than distant relatives. The exact percentage depends on the inheritance pattern in your family. Once the familial variant is known, precise numbers can be given.
Genetic testing confirmation: Retinal gene panels or broader sequencing can pinpoint the CORD17 change. A confirmed genetic diagnosis allows accurate risk estimates for siblings, children, and extended family. It can also connect you with gene-specific research or clinical trials.
Lifestyle risk factors
Cone-rod dystrophy 17 is a genetic condition; lifestyle habits do not cause it, but they can influence symptom burden, day-to-day function, and the pace of complications. This overview focuses on how lifestyle affects Cone-rod dystrophy 17, highlighting modifiable habits that can reduce retinal stress and protect remaining vision. The points below translate everyday choices into concrete effects on photophobia, contrast sensitivity, and potential progression.
Frequent unprotected exposure to bright sunlight or welding/arc lights can increase phototoxic stress on cones and rods, potentially worsening glare and color vision loss. Consistent use of UV400 sunglasses, hats, and appropriate tints can reduce discomfort and may help limit cumulative light-related damage.
Cigarette smoke raises oxidative stress and impairs retinal microcirculation, which can accelerate photoreceptor loss in cone-rod dystrophy 17. Quitting reduces oxidative load and may help preserve contrast sensitivity and central vision.
Diets low in leafy greens, colorful vegetables, and omega-3s may lower macular pigment and antioxidant defenses, potentially worsening light sensitivity and visual fatigue. A nutrient-dense diet can support retinal metabolism and functional vision, though it does not cure the disease.
Megadose vitamin A supplements can accumulate in the visual cycle and are discouraged in several photoreceptor dystrophies, including cone-rod patterns. Avoid high-dose vitamin A unless your ophthalmologist specifically recommends it.
Risk prevention
Cone-rod dystrophy 17 is an inherited eye condition, and there’s no known way to prevent it entirely. Still, you can lower the chance of complications and protect the vision you have. Routine eye care, glare control, and healthy habits can reduce day-to-day strain and risks from other eye problems. Prevention is about lowering risk, not eliminating it completely.
See an eye doctor regularly to track changes and adjust care. This helps catch treatable issues early, like cataracts or retinal swelling.
Wear UV-blocking sunglasses and a brimmed hat outdoors, and consider tints that reduce glare. This can ease light sensitivity in cone-rod dystrophy 17 and may lower light-related retinal stress.
Ask your doctor or pharmacist to review medicines for drugs that can affect the retina. If one is necessary, careful dosing and regular monitoring can reduce risk.
Smoking reduces blood flow to the retina and can speed damage. Stopping lowers strain on the eyes and improves overall health.
Transmission
Cone-rod dystrophy 17 is a genetic eye condition; it cannot be caught or spread between people. It is inherited when a DNA change is passed from a parent to a child, and depending on the specific gene involved, inheritance may be autosomal dominant (one changed copy is enough) or autosomal recessive (both copies need a change). In some families, the change happens for the first time in a child, so there may be no prior family history. The genetic transmission of Cone-rod dystrophy 17 affects the chance that future children or siblings will be affected, so genetic counseling and testing can clarify how Cone-rod dystrophy 17 is inherited in your family.
When to test your genes
Consider genetic testing if you have progressive vision changes (night blindness, color loss, central blur) or a family history of cone-rod dystrophy. Testing can confirm diagnosis, estimate inheritance risk, guide low-vision planning, and connect you to trials. If you’re planning a pregnancy, carrier testing and counseling can inform options.
Diagnosis
Changes in central vision, trouble with color, and light sensitivity often prompt an eye evaluation, which is how Cone-rod dystrophy 17 is usually picked up. Getting a diagnosis is often a turning point toward answers and support. Doctors combine what you describe with specialized eye tests and, when appropriate, genetic testing to confirm the cause. Early and accurate diagnosis can help you plan ahead with confidence.
Your eye doctor will ask about blurred central vision, color difficulties, glare, and later-onset night or peripheral vision problems. They will also ask when symptoms started and how they affect reading, screens, and driving.
Standard eye charts measure central sharpness, and color tests look for red-green or blue-yellow changes. These help flag early symptoms of Cone-rod dystrophy 17 and guide next steps.
The back of the eye is examined for subtle macular changes, pigment shifts, or thinning. Findings can be mild early on and become more noticeable as the condition progresses.
OCT creates cross-sectional images of the retina to assess the macula. Doctors look for thinning and disruption of the light-sensing layers that fit Cone-rod dystrophy 17.
Stages of Cone-rod dystrophy 17
Cone-rod dystrophy 17 does not have defined progression stages. The pattern and pace vary widely from person to person; early symptoms of Cone-rod dystrophy 17 may include light sensitivity, trouble seeing in bright conditions, color changes, and gradual central vision loss. Different tests may be suggested to help build a clear picture, such as vision and color testing, a retinal scan (OCT), visual field mapping, and electroretinography to check how the light-sensing cells are working. Genetic testing can sometimes confirm the exact subtype and guide family discussions about future risks.
Outlook and prognosis
Daily routines often adapt as cone-rod dystrophy 17 changes how clearly and comfortably someone can see, especially in bright light or at a distance. Many people ask, “What does this mean for my future?”, and the short answer is that vision typically worsens over years, not days, with ups and downs that can feel unpredictable. Everyone’s journey looks a little different. Some notice early symptoms of cone-rod dystrophy 17 such as light sensitivity and trouble reading fine print, while others first pick up more blind spots or difficulty seeing at night.
Looking at the long-term picture can be helpful. Prognosis refers to how a condition tends to change or stabilize over time. With cone-rod dystrophy 17, central vision usually declines first, followed by more problems in dim settings; many living with it retain some usable vision for tasks like navigating familiar spaces, especially with the right tools. Most people do not face life-threatening complications from this eye condition; mortality is generally similar to the general population, though injuries from falls or accidents can rise if vision loss is severe.
Early care can make a real difference by slowing complications and protecting remaining vision. Low-vision rehabilitation, tinted lenses for glare, orientation and mobility training, and smart-home lighting can help you stay independent at home and at work. Genetic testing can sometimes provide more insight into prognosis, since not everyone with the same gene change will have the same outlook. Talk with your doctor about what your personal outlook might look like, and ask about clinical trials or emerging therapies so you can plan ahead with confidence.
Long-term effects
Cone-rod dystrophy 17 tends to slowly reduce vision over years, starting with detail and color and later affecting night and side vision. Long-term effects vary widely, and the speed of change can be different even within the same family. Early symptoms of cone-rod dystrophy 17 often include trouble seeing at night and glare in bright light, which may progress to central vision loss. Over time, many people notice that daily tasks like reading small print or driving become harder, especially in dim or very bright settings.
Fine detail and sharpness often fade first, making faces, screens, and small print harder to see. This loss can gradually progress from mild blurring to more severe central blind spots.
Colors can look washed out or confusing, especially reds and greens. Over time, color problems can make tasks like matching clothes or reading color-coded charts difficult.
Bright light and glare can feel harsh or painful. Many find vision briefly “whites out” when moving from dark to bright environments.
Seeing in low light typically becomes harder as the condition advances. Dim restaurants, evening walks, or driving at night can become challenging.
How is it to live with Cone-rod dystrophy 17?
Living with cone-rod dystrophy 17 often means adapting to changing vision over time: colors and fine details fade first, bright light can feel harsh, and later on dim or nighttime vision may also be affected, making reading, driving, and screen use more challenging. Many find that practical tools—high-contrast settings, larger fonts, tinted lenses, controlled lighting, and orientation or mobility training—help keep daily life moving, alongside regular low-vision care and occupational therapy. Family, friends, and coworkers may need to adjust expectations and environments—clearer labels, better lighting, shared navigation on outings—while offering patience and support as tasks take new routes rather than stopping altogether. With planning, assistive technology, and community, people with this condition can stay engaged at work, at school, and in relationships, even as they reimagine how they do familiar things.
Treatment and drugs
Cone-rod dystrophy 17 treatment focuses on easing symptoms, protecting vision that remains, and supporting daily life, since no therapy can yet reverse the condition. Regular eye exams track changes, update glasses or contact lenses, and address complications like cataracts or swelling at the back of the eye. Tinted lenses, UV-blocking sunglasses, and low-vision aids (such as magnifiers, high-contrast devices, and screen readers) can reduce glare and make reading, driving in early stages, and work tasks more manageable. Although living with Cone-rod dystrophy 17 can feel overwhelming, many people manage their symptoms and live fulfilling lives. Genetic counseling, mobility training, workplace and school accommodations, and, in select cases, participation in clinical trials or registries may also be discussed with your eye specialist.
Non-drug treatment
Living with cone-rod dystrophy 17 can affect reading, driving, school, and work long before major vision changes. Non-drug treatments often lay the foundation for staying independent and safe. Early symptoms of cone-rod dystrophy 17 can include glare sensitivity, fading colors, and difficulty in dim light, and these approaches aim to help you adapt as changes unfold.
One-on-one training helps you use remaining vision more effectively. Specialists teach practical techniques and match you with tools that fit your goals. Plans can be updated as your vision changes.
Screen readers, text-to-speech, and magnification software make print and screens accessible. Smartphone accessibility features can boost independence on the go. These tools help many with cone-rod dystrophy 17 keep up with reading and communication.
Training covers safe street crossing, white cane skills, and route planning. Practice in real settings builds confidence and safety. This is valuable as cone-rod dystrophy 17 can affect both day and night navigation.
Bright, adjustable task lights reduce eye strain, and anti-glare shades help indoors and outdoors. High-contrast labels and bold markers make details stand out. These adjustments often ease glare sensitivity with cone-rod dystrophy 17.
Your genes may have an impact on how drugs work for you
Some medicines for vision symptoms can work differently because gene changes in cone‑rod dystrophy 17 affect how your body processes drugs. Genetic testing can guide dosing or drug choice, helping your care team tailor safer, more effective treatment.
Pharmacological treatments
There’s currently no approved medicine that can stop or reverse Cone-rod dystrophy 17, but several drugs may help treat complications that affect vision. Medicines mainly aim to reduce retinal swelling or control abnormal blood vessels that can worsen sight. Drugs that target symptoms directly are called symptomatic treatments. Medicines don’t change early symptoms of cone-rod dystrophy 17, like glare or color loss, but they can help if swelling or bleeding develops.
Eye-drop carbonic anhydrase inhibitors such as dorzolamide or brinzolamide can reduce cystoid macular edema (fluid in the retina). This may sharpen central vision or ease distortion for some people. Stinging or a bitter taste can occur but usually settles.
Tablets like acetazolamide or methazolamide may be used if swelling is more stubborn. They can improve retinal fluid control but need monitoring for side effects such as tingling, fatigue, or kidney stone risk. Ask your doctor why a specific drug was recommended for you.
Ranibizumab, aflibercept, or bevacizumab can treat choroidal neovascularization (leaky new vessels) if it develops. Injections are given into the eye at intervals and can stabilize or improve vision by drying the leakage. Infection risk is low but real, so follow aftercare closely.
Ketorolac, nepafenac, or bromfenac eye drops, and in some cases steroid drops or injections like triamcinolone or a dexamethasone implant, may be used for persistent retinal swelling. These options can help when carbonic anhydrase inhibitors aren’t enough. Eye pressure checks are important because steroids can raise pressure or speed cataract formation.
Genetic influences
Some families notice a pattern of early color and daylight vision problems across generations. Cone-rod dystrophy 17 is caused by a change in a single gene that disrupts how the retina’s light-sensing cells function. Family history is one of the strongest clues to a genetic influence. Most cases are inherited, though sometimes the gene change appears for the first time in a child, with no prior family history. The exact gene change and how strongly it acts can shape the age symptoms start and how fast vision changes, which is why early symptoms of Cone-rod dystrophy 17 can differ even between relatives. Genetic testing and counseling can clarify the pattern in your family, estimate risks for children, and guide eligibility for research or future treatments.
Is Cone-rod dystrophy 17 genetic?
Genetics play a central role in cone-rod dystrophy 17; it’s caused by inherited changes in a specific gene. Variants can affect age of onset, severity, and vision loss pattern. Family history matters, so genetic testing and counseling are often recommended.
Pharmacogenetics—how genetics influence drug effects
Genetic findings play a central role in how care is planned for Cone-rod dystrophy 17. Pinpointing the exact gene change can help your team decide whether you might qualify for research studies—such as gene or RNA-based approaches—and avoid options unlikely to fit your subtype. For day-to-day management—like using a carbonic anhydrase inhibitor (a glaucoma-type medicine sometimes used for macular swelling) or medicines during eye procedures—dosing usually follows standard practice, because there are no proven drug–gene rules specific to Cone-rod dystrophy 17 yet. In some inherited retinal diseases involving ABCA4, for example, high-dose vitamin A is generally avoided; depending on your results, your specialist may tailor nutrition or supplements in a similar, gene-aware way. Advances in pharmacogenetics are helping doctors match people to gene-specific treatments for Cone-rod dystrophy 17 as they become available. Genetics is only one factor, though—age, other health conditions, and the medicines you take also influence what’s safe and how well treatments work.
Interactions with other conditions
When another eye condition is also in the picture, vision challenges can add up—glare from cataracts, for example, can stack on top of the light sensitivity many already manage. Cone-rod dystrophy 17 is often limited to the eyes, but it can coexist with common problems like cataracts, glaucoma, or high myopia, and each of these can further reduce clarity, contrast, or side vision. Early symptoms of Cone-rod dystrophy 17 can be mistaken for other retinal or macular diseases, so overlaps may delay diagnosis or make it harder to tease apart what’s causing which changes. Diabetes-related eye disease can also compound vision loss, and careful control of blood sugar helps protect the retina in people with Cone-rod dystrophy 17. Some medicines can stress the retina or affect color and night vision, so it’s worth reviewing your medication list if new visual symptoms appear. Ask if any medications for one condition might interfere with treatment for another.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described trouble seeing in dim light, colors looking washed out, and central vision fading over time—signs that fit what we now call cone-rod dystrophy 17. In a classroom, a child might squint at bright overhead lights yet struggle to read the board. Later in life, driving at dusk can become stressful as glare worsens and details blur. Families sometimes recall relatives who wore shaded glasses indoors or held books very close to make out letters.
From early theories to modern research, the story of cone-rod dystrophy 17 has moved from careful observation to gene-level understanding. Early doctors noted a pattern: central vision and color perception declined first, then night vision and side vision followed. At the time, they could only group people by the way their vision changed and how the retina looked under examination. As retinal imaging improved, these patterns became clearer and more consistent, showing a characteristic thinning of the light-sensing cells at the back of the eye.
In recent decades, awareness has grown as researchers matched these clinical patterns with specific genetic changes. A key step was recognizing that “cone-rod dystrophy” is not a single condition but a family of related disorders. The “17” indicates one of the genetic subtypes, tied to changes in a particular gene. This helped explain why two people in the same family might share early symptoms of cone-rod dystrophy 17 yet lose vision at different speeds or be more sensitive to light than others.
Advances in genetics also clarified inheritance. Generations of similar symptoms made sense once testing showed whether the gene change was passed in an autosomal dominant or recessive pattern, or arose for the first time in an individual. With better family histories and access to genetic counseling, many living with cone-rod dystrophy 17 could understand recurrence risks and make informed choices about screening and support.
Over time, descriptions became more precise as imaging techniques like optical coherence tomography and widefield photography showed how the cone-rich center of the retina thins early, while rod changes appear later. Functional tests, including color vision charts and electroretinography, confirmed what people reported in daily life: colors lose vibrancy, fine print becomes harder to read, and glare can be disabling long before complete vision loss occurs.
Today’s picture of cone-rod dystrophy 17 is the product of that steady progress. The name reflects both the order in which retinal cells are affected and the specific gene subtype. Historical differences highlight why careful examination and genetic testing matter: they sort similar-looking conditions into clearer groups, guide prognosis, and open doors to research. While treatments are still under study, the path from early observation to genetic discovery has laid the groundwork for future therapies and more tailored care.